Accessibility issues or difficulties with this website?
Call 919-962-2073 or email hchsadministration@unc.edu.

Blood metabolites predicting mild cognitive impairment in the study of Latinos-investigation of neurocognitive aging (HCHS/SOL).

TitleBlood metabolites predicting mild cognitive impairment in the study of Latinos-investigation of neurocognitive aging (HCHS/SOL).
Publication TypePublication
Year2022
AuthorsHe S, Granot-Hershkovitz E, Zhang Y, Bressler J, Tarraf W, Yu B, Huang T, Zeng D, Wassertheil-Smoller S, Lamar M, Daviglus M, Marquine MJ, Cai J, Mosley T, Kaplan R, Boerwinkle E, Fornage M, DeCarli C, Kristal B, González HM, Sofer T
JournalAlzheimers Dement (Amst)
Volume14
Issue1
Paginatione12259
Date Published2022
ISSN2352-8729
Abstract

INTRODUCTION: Blood metabolomics-based biomarkers may be useful to predict measures of neurocognitive aging.METHODS: We tested the association between 707 blood metabolites measured in 1451 participants from the Hispanic Community Health Study/Study of Latinos (HCHS/SOL), with mild cognitive impairment (MCI) and global cognitive change assessed 7 years later. We further used Lasso penalized regression to construct a metabolomics risk score (MRS) that predicts MCI, potentially identifying a different set of metabolites than those discovered in individual-metabolite analysis.RESULTS: We identified 20 metabolites predicting prevalent MCI and/or global cognitive change. Six of them were novel and 14 were previously reported as associated with neurocognitive aging outcomes. The MCI MRS comprised 61 metabolites and improved prediction accuracy from 84% (minimally adjusted model) to 89% in the entire dataset and from 75% to 87% among apolipoprotein E ε4 carriers.DISCUSSION: Blood metabolites may serve as biomarkers identifying individuals at risk for MCI among US Hispanics/Latinos.

DOI10.1002/dad2.12259
Alternate JournalAlzheimers Dement (Amst)
PubMed ID35229015
PubMed Central IDPMC8865745
MS#: 
0968
ECI: 
Manuscript Status: 
Published